Decoy Therapeutics has secured funding to begin clinical trials for its programs targeting respiratory illnesses.

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical ...

) has been revised to $30.60 / share. This is an increase of 1,100.00% from the prior estimate of $2.55 dated February 21, 2026. The price target is an average of many targets provided by analysts.

Track conference calls, annual meetings, summits, analyst days and other corporate events scheduled for Decoy Therapeutics Inc. Use the full market events calendar to scan activity across all tickers.

Short interest in Decoy Therapeutics Inc (NASDAQ:DCOY) increased during the last reporting period, rising from 19.30K to 23.25K. This put 4.37% of the company's publicly available shares short. Based ...

As of 2:16:23 PM EDT. Market Open.

DCOY is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of DCOY shares has decreased $0.35 since the market last closed. This is a 5.76 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.